1.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23(1): 56–62.
2.Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382–389.
3.Koran, LM, Hamilton, SH, Hertzman, M, etal. Predicting response to fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1995; 15(6): 421–427.
4.Szegedi, A, Muller, MJ, Anghelescu, I, etal. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003; 64(4): 413–420.
5.Szegedi, A, Jansen, WT, van Willigenburg, AP, etal. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009; 70(3): 344–353.
6.Kok, RM, van Baarsen, C, Nolen, WA, Heeren, TJ. Early response as predictor of final remission in elderly depressed patients. Int J Geriatr Psychiatry. 2009; 24(11): 1299–1303.
7.Lin, CH, Lane, HY, Chen, CC, Juo, SH, Yen, CF. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011; 31(2): 187–193.
9.Hirschfeld, RM, Dunner, DL, Keitner, G, etal. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol Psychiatry. 2002; 51(2): 123–133.
10.Hirschfeld, RM, Montgomery, SA, Keller, MB, etal. Social functioning in depression: a review. J Clin Psychiatry. 2000; 61(4): 268–275.
11.Bech, P. Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs. 2005; 19(4): 313–324.
12.Papakostas, GI. Major depressive disorder: psychosocial impairment and key considerations in functional improvement. Am J Manag Care. 2009; 15(11 Suppl): S316–S321.
13.Trivedi, MH, Corey-Lisle, PK, Guo, Z, etal. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol. 2009; 24(3): 133–138.
14.Fifer, SK, Buesching, DP, Henke, CJ, etal. Functional status and somatization as predictors of medical offset in anxious and depressed patients. Value Health. 2003; 6(1): 40–50.
15.Hunkeler, EM, Spector, WD, Fireman, B, Rice, DP, Weisner, C. Psychiatric symptoms, impaired function, and medical care costs in an HMO setting. Gen Hosp Psychiatry. 2003; 25(3): 178–184.
16.Jain, G, Roy, A, Harikrishnan, V, etal. Patient-reported depression severity measured by the PHQ-9 and impact on work productivity: results from a survey of full-time employees in the United States. J Occup Environ Med. 2013; 55(3): 252–258.
17.Stewart, WF, Ricci, JA, Chee, E, Hahn, SR, Morganstein, D. Cost of lost productive work time among US workers with depression. JAMA. 2003; 289(23): 3135–3144.
18.Simon, GE, Revicki, D, Heiligenstein, J, etal. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000; 22(3): 153–162.
19.Guico-Pabia, CJ, Fayyad, RS, Soares, CN. Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis. Int Clin Psychopharmacol. 2012; 27(1): 1–7.
20.Mauskopf, JA, Simon, GE, Kalsekar, A, etal. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety. 2009; 26(1): 83–97.
21.Sheehan, DV. Sheehan Disability Scale. In Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 113–115.
22.Endicott, J, Dorries, KM. Functional outcomes in MDD: established and emerging assessment tools. Am J Manag Care. 2009; 15(11 Suppl): S328–S334.
23.Soares, CN, Fayyad, RS, Guico-Pabia, CJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol. 2014; 34(1): 57–65.
25.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.Washington, DC: American Psychiatric Publishing; 1994.
26.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th ed, text rev. Washington, DC: American Psychiatric Publishing; 2000.
27.Clayton, A, Kornstein, SG, Dunlop, BW, etal. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013; 74(10): 1010–1017.
28.Dunlop, BW, Reddy, S, Yang, L, etal. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011; 31(5): 569–576.
29.Lipman, RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull. 1982; 18(4): 69–77.
31.Cleary, P, Guy, W. Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res. 1977; 1(1-2): 115–120.
32.Sheehan, KH, Sheehan, DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008; 23(2): 70–83.
33.Lam, RW, Kennedy, SH, Grigoriadis, S, etal. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117(Suppl 1): S26–S43.
35.Farabaugh, A, Sonawalla, S, Johnson, DP, etal. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010; 22(3): 166–171.
36.Henkel, V, Seemuller, F, Obermeier, M, etal. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 2009; 115(3): 439–449.
37.McIntyre, RS. When should you move beyond first-line therapy for depression? J Clin Psychiatry. 2010; 71(Suppl 1): 16–20.
38.Gallop, RJ. Determination and interpretation of the OOP for ROC's with PROC LOGISTIC. In Proceedings of the NorthEast SAS Users Group. Baltimore, MD: NorthEast SAS Users Group; 2001: 777–782.
39.Adler, DA, McLaughlin, TJ, Rogers, WH, etal. Job performance deficits due to depression. Am J Psychiatry. 2006; 163(9): 1569–1576.
40.Trivedi, MH, Morris, DW, Wisniewski, SR, etal. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013; 170(6): 633–641.
41.Liebowitz, MR, Manley, AL, Padmanabhan, SK, etal. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008; 24(7): 1877–1890.
42.Boyer, P, Montgomery, S, Lepola, U, etal. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008; 23(5): 243–253.
43.Tourian, KA, Padmanabhan, SK, Groark, J, Brisard, C, Farrington, D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009; 31(Pt 1): 1405–1423.
44.Iwata, N, Tourian, KA, Hwang, E, Mele, L, Vialet, C, for the Study 3359 Investigators. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract. 2013; 19(1): 5–14.
45.Liebowitz, MR, Tourian, KA, Hwang, E, Mele, L, for the Study 3362 Investigators. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry. 2013; 13(1): 94.